Los Altos Hills, CA, United States of America

Aaron Weitzman

USPTO Granted Patents = 3 



Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Los Altos Hills, CA (US) (2020 - 2022)
  • Menlo Park, CA (US) (2023)

Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Aaron Weitzman

Introduction

Aaron Weitzman is a notable inventor based in Los Altos Hills, California. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of three patents to his name, Weitzman has focused on developing advanced methods and formulations to combat cancer effectively.

Latest Patents

Weitzman's latest patents include a dosage form of cabozantinib and a method of employing this dosage form to treat cancer. This invention relates specifically to the formulation of cabozantinib, which is crucial in the fight against cancer. Another significant patent involves methods of using c-Met modulators, which describe ways to treat cancer by administering a specific compound in combination with other cancer treatments.

Career Highlights

Aaron Weitzman is currently associated with Exelixis, Inc., a company known for its focus on developing innovative cancer therapies. His work at Exelixis has allowed him to contribute to groundbreaking research and development in oncology.

Collaborations

Weitzman has collaborated with several professionals in his field, including Dana T Aftab and Thomas Mueller. These collaborations have further enhanced his research and development efforts in cancer treatment.

Conclusion

Aaron Weitzman's contributions to cancer treatment through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to impact the field positively, offering hope for improved cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…